<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Masculinizing Hormonal Therapy</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Masculinizing Hormonal Therapy</md:title>
    <md:content-id>m00458</md:content-id>
    <md:uuid>5b6ba77b-01aa-4405-ae1d-a9cca09750d6</md:uuid>
  </metadata>
  <content>
    <section class="learning-objectives" id="sect-00001">
    <title>Learning Outcomes</title>
    <para id="para-00001">By the end of this section, you should be able to:</para>
    <list list-type="bulleted" id="list-00001">
    <item>Identify the characteristics of masculinizing hormonal drugs used for transgender and nonbinary therapy.</item>
    <item>Explain the indications, actions, adverse reactions, and interactions of masculinizing hormonal drugs used for transgender and nonbinary therapy.</item>
    <item>Describe nursing implications of masculinizing hormonal drugs used for transgender and nonbinary therapy.</item>
    <item>Explain the client education related to masculinizing hormonal drugs used for transgender and nonbinary therapy.</item>
    </list>
    </section>
    <para id="para-00002">The hormones used for men’s reproductive health, covered in <link document="m00448">Reproductive Health Drugs</link>, are also discussed in this chapter; complete information for the drugs can be found there. Discussion in this chapter focuses on use of the medications to develop male secondary sex characteristics in individuals who were assigned female at birth and choose to undergo <term class="no-emphasis" id="term-00001">female-to-male (FTM) transition</term>. Further transition would include chest masculinization surgery, hysterectomy, and creation of external male genitalia (Mount Sinai, n.d.-a).</para>
    <para id="para-00003">The overall effects of masculinizing hormonal drugs on the female body include the growth of facial hair and increased body hair, deepening of the voice, redistribution of subcutaneous fat, increased muscle mass, hairline recession, and, possibly, male pattern baldness (<link target-id="fig-00001" document="m00458"/>). Sexual and gonadal effects include an increase in libido, clitoral growth, vaginal dryness, and cessation of menses (Deutsch, 2016; Hembree et al., 2017; Mayo Clinic, 2021b; Unger, 2016).</para>
    <para id="para-00004">Although male hormone therapy produces some of the secondary male characteristics in females who are transitioning to males, it also has adverse effects that may be problematic. Possible complications include weight gain, acne, male pattern baldness, sleep apnea, elevated cholesterol, hypertension, polycythemia, type 2 diabetes, infertility, deep vein thrombosis, pulmonary embolism, increased risk for heart disease, drying and thinning of the vaginal lining, pelvic pain, and clitoral discomfort (Mayo Clinic, 2021b).</para>
    <para id="para-00005">One major consideration for any transgender male is the danger the hormones pose to a fetus. Testosterone in particular is teratogenic, but other hormones are as well (Rodriguez-Wallberg et al., 2022). Thus, the nurse must ensure that a female client transitioning to male has had a negative pregnancy test.</para>
    <figure class="scaled-down" id="fig-00001">
    <media alt="A diagram shows the areas of the body that are altered by drugs used for F T M transition. There is hair loss at the scalp, increased oiliness in the skin, and acne. Increased muscle mass and strength occur in the arms. The voice deepens. Facial and body hair grows. Fat redistribution occurs in the stomach. Clitoral enlargement and vaginal atrophy also occur.">
    <image mime-type="image/png" src="../../media/PHA_Figure_37_03_003.png"/></media>
    <caption>Drugs used for female-to-male transition affect many areas of the body. (attribution: Copyright Rice University, OpenStax, under CC BY 4.0 license)</caption>
    </figure>
        <section id="sect-00003">
    <title>Androgens</title>
    <para id="para-00006">Androgens are a group of male hormones, including testosterone. They can be endogenous (produced in the body) or synthetic (developed in a laboratory). All forms of androgens assist with the development of male secondary sex characteristics (Deutsch, 2016; Hembree et al., 2017; Mayo Clinic, 2021b; T’Sjoen et al., 2019; Unger, 2016). In the case of FTM transition, synthetic androgens must be administered exogenously because the female body does not produce them.</para>
    <para id="para-00007">Androgens increase the retention of nitrogen, sodium, potassium, and phosphorous and decrease the urinary excretion of calcium. Therefore, a female client transitioning to male should be evaluated for any underlying condition that would be affected by increased levels of these electrolytes, primarily cardiac and renal disorders (DailyMed, <emphasis effect="italics">Testosterone cypionate,</emphasis> 2018).</para>
    <note class="safety-alert" id="note-00001">
    <title>Androgens and Diabetic Medication</title>
    <para id="para-00008">Androgens can decrease blood glucose levels in clients with diabetes. Dosages of insulin and other hypoglycemic medications must be monitored and possibly decreased to prevent dangerous hypoglycemic events.</para>
    <para id="para-00009">(Source: DailyMed, <emphasis effect="italics">Testopel</emphasis>, 2018)</para>
    </note>
    <section id="sect-00004">
    <title>Danazol</title>
    <para id="para-00010">Danazol is a synthetic androgen that inhibits pituitary gonadotropins and in turn suppresses ovarian response to the pituitary. Danazol has weak properties and acts similarly to testosterone. In females it causes masculinization effects. Generally, the pituitary-suppressive action of danazol is reversible.</para>
    <para id="para-00011">Contraindications to danazol include hypersensitivity; undiagnosed abnormal genital bleeding; markedly impaired hepatic, renal, or cardiac function; pregnancy; breastfeeding; androgen-dependent tumor; and active thrombosis or thromboembolic disease or a history of such events. Danazol may cause some fluid retention, so it should be used cautiously in clients with conditions that may be affected by excess fluid, including epilepsy, migraine, cardiac or renal dysfunction, polycythemia, and hypertension. Danazol should also be used with caution in diabetic clients (DailyMed, <emphasis effect="italics">Danazol</emphasis>, 2023).</para>
    </section>
    <section id="sect-00005">
    <title>Testosterone</title>
    <para id="para-00012">Testosterone is a hormone responsible for the development of male sex organs and secondary sex characteristics. These characteristics include the male pattern of hair distribution (pubic area, axillae, face, and chest), deepening of the voice, heavier bone structure, increased hematocrit, and differences in fat distribution (T’Sjoen et al., 2019). Testosterone undecanoate is an androgen and anabolic steroid medication used mainly to treat low testosterone levels in men. It is also used to promote secondary sex characteristics in females transitioning to males (DailyMed, <emphasis effect="italics">Aveed</emphasis>, 2021; T’Sjoen et al., 2019).</para>
    <para id="para-00013">A realistic target for hormone therapy for FTM transition is to administer testosterone until testosterone levels are within the typical male physiologic range (320–1000 ng/dL).</para>
    <para id="para-00014"><link target-id="table-00001" document="m00458"/> lists common forms of testosterone and typical routes and dosing for adult clients.</para>
          <table class="vertically-tight" id="table-00001">
         <tgroup cols="2">
          <colspec colnum="1" colname="c1" colwidth="1*"/>
          <colspec colnum="2" colname="c2" colwidth="2*"/>
         <thead>
          <row>
          <entry valign="top" align="center"><span class="blue-text">Drug</span></entry>
          <entry valign="top" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
          </row>
          </thead>
          <tbody>
          <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00002">Testopel pellet</term></entry>
    <entry valign="top" align="left">75 mg subcutaneous implant (6 pellets implanted every 3–4 months).</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00003">Testosterone enanthate</term><newline/>
      (<term class="no-emphasis" id="term-00004">Delatestryl</term>)<newline/>
      <term class="no-emphasis" id="term-00005">Testosterone cypionate</term><newline/>
    (<term class="no-emphasis" id="term-00006">Depo-Testosterone</term>)</entry>
    <entry valign="top" align="left">50–100 mg intramuscularly/subcutaneously weekly or 100–200 mg intramuscularly every 2 weeks.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00007">Testosterone gel</term></entry>
    <entry valign="top" align="left">50–100 mg daily.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00008">Testosterone patch</term><newline/>
      (AndroGel, Androderm)</entry>
    <entry valign="top" align="left">2.5–7.5 mg daily transdermally.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00009">Testosterone undecanoate</term></entry>
    <entry valign="top" align="left">1000 mg intramuscularly every 12 weeks or 750 mg intramuscularly every 10 weeks.</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Emphasis Table: Testosterone</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Coleman et al., 2022)</caption>
    </table>
    </section>
    </section>
    <section id="sect-00006">
    <title>Fluoxymesterone and Methyltestosterone</title>
    <para id="para-00015">Fluoxymesterone and methyltestosterone are anabolic steroids. Their use in FTM transition is to assist in the development of secondary male sex characteristics. Contraindications and precautions include pregnancy; diabetes; and liver, renal, or cardiac disease. Adverse effects include acne, heart or blood vessel problems, stroke, liver problems, mental or mood problems, and infertility. For more information regarding anabolic steroids, see <link document="m00448">Reproductive Health Drugs</link>.</para>
    </section>
    <section id="sect-00007">
    <title>Progesterone</title>
    <para id="para-00016">Progesterone has some minor anabolic and adrenergic properties that can help with development of male characteristics (increased hair growth) and suppression of female characteristics (decreased breast size). See <link document="m00448">Reproductive Health Drugs</link> for more information about progesterone. For individuals who do not want therapies that contain estrogen, are at risk for thromboembolic complications, or have other contraindications, progesterone is an alternative to estrogen.</para>
    <note class="clinical-tip" id="note-00002">
    <title>Target for Hormone Therapy</title>
    <para id="para-00017">A practical target for hormone therapy for FTM transition is to administer testosterone until testosterone levels reach the typical cisgender male physiologic range (320–1000 ng/dL).</para>
    <para id="para-00018">(Source: Hembree et al., 2017)</para>
    </note>
    <para id="para-00019"><link target-id="table-00002" document="m00458"/> is a drug prototype table for masculinizing hormones featuring the testosterone patch. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
    <table class="vertically-tight" id="table-00002">
    <tgroup cols="2">
    <colspec colnum="1" colname="col1" colwidth="1*"/>
    <colspec colnum="2" colname="col2" colwidth="1*"/>
    <tbody>
    <row>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
    Masculinizing hormone<newline count="2"/>
    <emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
    Suppresses estrogen and enhances testosterone</entry>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
    2.5–7.5 mg daily transdermally.</entry>
    </row>
    <row>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
    For use in FTM transgender transition<newline count="2"/>
    <emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
    Increased muscle mass<newline/>
    Increased body hair<newline/>
    Increased libido<newline/>
    Voice deepening<newline/>
    Cessation of menses<newline/></entry>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
    Oral anticoagulants<newline/>
    Hyperglycemic drugs (doses may need to be decreased because the testosterone patch may decrease blood glucose levels in diabetic clients)<newline/>
    Corticosteroids<newline count="2"/>
    <emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
    No significant interactions</entry></row>
    <row>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
    Application site pruritus, blistering, erythema<newline/>
    Back pain<newline/>
    Headache<newline/>
    Depression<newline/>
    Gastrointestinal bleeding<newline/>
    Acne<newline/>
    Pelvic pain<newline/>
    Decreased libido</entry>
    <entry valign="top">
    <emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
    Pregnancy<newline/>
    Presence of a hormone-sensitive cancer<newline/>
    History of blood clots (deep vein thrombosis or pulmonary embolism)<newline/>
    Serious cardiac, hepatic, or renal disease<newline/>
    Significant mental health conditions, such as severe depression or psychosis, that have not been addressed</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Prototype Table: Testosterone Patch</emphasis> (sources: https://dailymed.nlm.nih.gov/dailymed/; Coleman et al., 2022)</caption>
    </table>
    </section>
    <section id="sect-00008">
    <title>Nursing Implications</title>
    <para id="para-00020">The nurse should do the following for clients who are taking masculinizing hormones:</para>
    <list list-type="bulleted" id="list-00002">
    <item>Assess baseline health, including underlying medical conditions, current medications, and pertinent laboratory and diagnostic results.</item>
    <item>Be cognizant of the client’s feelings, values, and culture in order to render sensitive care.</item>
    <item>Be knowledgeable about drug actions, side effects, contraindications, and precautions and assess the client’s knowledge and understanding.</item>
    <item>Obtain a hematocrit and lipid profile before the client starts hormone therapy and at follow-up visits.</item>
    <item>Monitor virilizing and adverse effects every 3 months for the first year and then every 6–12 months.</item>
    <item>Assess serum testosterone at follow-up visits, with a practical target in the male range of 400–700 ng/dL. Peak levels for clients taking parenteral testosterone can be measured 24–48 hours after injection. Trough levels can be measured immediately before injection.</item>
    <item>Screen for bone mineral density before clients at risk for osteoporosis start hormone therapy. Otherwise, screening can start at age 60 or, if sex hormone levels are consistently low, earlier.</item>
    <item>Screen clients with cervixes or breasts appropriately.</item>
    <item>Ensure that the client understands issues related to family planning and has had an opportunity to meet with a family planning specialist. Resources are available for various options, such as freezing eggs or donating eggs to a partner or gestational surrogate.</item>
    <item>Ensure that the client is aware of and has access to resources such as community organizations, specialty clinics and hospitals, and support groups.</item>
    <item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
    </list>
    <note class="client-teaching" id="note-00003">
    <para id="para-00021"><emphasis effect="bold">The client taking a masculinizing hormone should:</emphasis></para>
    <list list-type="bulleted" id="list-00003">
    <item>Know the names, actions, effects, side effects, contraindications, and precautions related to each medication.</item>
    <item>Understand the schedule for medication administration—time, dosage, and route.</item>
    <item>Know how to self-administer parenteral or transdermal medication.</item>
    <item>Be aware of drug–drug, drug–food, and drug–herbal interactions as indicated for specific drugs, such as testosterone and warfarin and diabetes medications.</item>
    <item>Notify the health care provider if any of the following occur: 
    <list list-type="bulleted" id="list-00004">
    <item>Serious reactions to any drug, including swelling of the mouth, lips, or tongue; respiratory problems; or skin rash</item>
    <item>Any adverse effect that becomes too uncomfortable (e.g., clitoral enlargement, acne)</item>
    <item>New onset of diabetes or a thyroid disorder; substantial weight changes; subjective or objective evidence of regression of virilization; or new symptoms potentially precipitated or exacerbated by hormone imbalances, such as hot flashes, pelvic cramping, or bleeding</item>
    </list></item>
    <item>Be aware of fertility considerations and the available options.</item>
    <item>Continue to attend wellness visits and schedule routine diagnostic procedures such as for prostate and breast cancer prevention.</item>
    </list>
    </note>
    <note class="link-to-learning" id="note-00004">
    <title>Scholarly Articles </title>
    <list list-type="bulleted" id="list-00005">
    <item>This article from the journal <emphasis effect="italics">Brain</emphasis> discusses <link url="https://openstax.org/r/doiorg10.093brain">the role of the brain in determining sex and gender identity</link>.</item>
    <item>This article from the <emphasis effect="italics">International Journal of Environmental Research and Public Health</emphasis> explores the <link url="https://openstax.org/r/trulylistento">feelings of nonbinary individuals who encounter the health care system</link>.</item>
    </list>
    </note>
    <note class="black-box" id="note-00005">
    <para id="para-00022"><emphasis effect="bold">Danazol</emphasis></para>
    <para id="para-00023">Danazol can result in androgenic effects on the female fetus. If a client becomes pregnant while on therapy, the drug should be discontinued. A pregnancy test is required before clients of childbearing age begin therapy, and a nonhormonal method of contraception should be used during therapy.</para>
    <para id="para-00024"><emphasis effect="bold">Testosterone</emphasis></para>
    <para id="para-00025">Virilization has been reported in children who were secondarily exposed to <emphasis effect="bold">topical testosterone</emphasis> gel/solutions. Children should avoid contact with adult application sites for these products.</para>
    <para id="para-00026">Serious reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope, and episodes of anaphylaxis, have been reported to occur during or immediately after the administration of <emphasis effect="bold">testosterone undecanoate</emphasis> injection. This product is available through a REMS program and requires that clients be observed in the health care setting for 30 minutes in order to provide appropriate medical treatment in the event of serious reactions or anaphylaxis.</para>
    <para id="para-00027"><emphasis effect="bold">Testosterone enanthate</emphasis> (subcutaneous) and <emphasis effect="bold">testosterone undecanoate</emphasis> (oral) can cause blood pressure increases that can increase the risk for major adverse cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death, especially in clients with cardiovascular risk factors or established cardiovascular disease. Before initiating testosterone enanthate, consider the client’s baseline cardiovascular risk and ensure blood pressure is adequately controlled. Additionally, blood pressure should be monitored throughout the treatment period and risk versus benefits evaluated for clients who develop cardiovascular risk factors or disease while on treatment.</para>
    </note>
       </section>
    <section class="chapter-summary" id="sect-00009">
    <para id="para-00028">This chapter began by defining terms used to describe the transgender and nonbinary population. The terms overlap and can have different meanings depending on the individual’s preference and culture, societal norms, and the historical meaning of the terms. The nurse who cares for transgender and nonbinary clients should determine which terms are appropriate or preferred for each client. The chapter listed several websites as resources for both clients and health care professionals. The websites define terms, explore issues related to transgender and nonbinary individuals, and present information on community organizations that provide support.</para>
    <para id="para-00029">This chapter covered the medications used by some transgender and nonbinary individuals. Although typical health conditions can be part of the health care needs of this population, the chapter specifically focused on hormonal and other medications used for individuals transitioning partially or completely into a gender opposite the sex assigned at birth or for individuals who do not identify with one gender. One learning tip that can help the reader is to recognize that the hormonal drugs in this chapter are the same as those in <link document="m00448">Reproductive Health Drugs</link>. Thus, the content is not new, but the application is different. Side effects of male hormones become the intended or therapeutic effects when used in FTM transgender transition treatment, and vice versa.</para>
    <para id="para-00030">The medications were divided into two sections: feminizing hormones and masculinizing hormones. This classification does not mean that gender transitioning can only be one or the other; it was just intended to simplify the sections for readers, with the caveat that clients need to be treated on an individual basis.</para>
    <para id="para-00031">Above all, nurses who care for clients who are transgender, nonbinary, or do not fit society’s traditional ideas of what is acceptable must face their own biases and preconceptions. These clients deserve respect and compassion.</para>
    </section>
          <section class="review-questions" id="sect-00010">
          <title>Review Questions</title>
          <exercise id="exer-00001"><problem id="prob-00001"><para id="para-00032"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec1_RQ1"/></para></problem></exercise>
          <exercise id="exer-00002"><problem id="prob-00002"><para id="para-00033"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec2_RQ2"/></para></problem></exercise>
          <exercise id="exer-00003"><problem id="prob-00003"><para id="para-00034"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec3_RQ3"/></para></problem></exercise>
          <exercise id="exer-00004"><problem id="prob-00004"><para id="para-00035"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec2_RQ4"/></para></problem></exercise>
          <exercise id="exer-00005"><problem id="prob-00005"><para id="para-00036"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec2_RQ5"/></para></problem></exercise>
          <exercise id="exer-00006"><problem id="prob-00006"><para id="para-00037"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec2_RQ6"/></para></problem></exercise>
          <exercise id="exer-00007"><problem id="prob-00007"><para id="para-00038"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec3_RQ7"/></para></problem></exercise>
          <exercise id="exer-00008"><problem id="prob-00008"><para id="para-00039"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec3_RQ8"/></para></problem></exercise>
          <exercise id="exer-00009"><problem id="prob-00009"><para id="para-00040"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec2_RQ9"/></para></problem></exercise>
          <exercise id="exer-00010"><problem id="prob-00010"><para id="para-00041"><link class="os-embed" url="#exercise/PHAR_Ch37_Sec3_RQ10"/></para></problem></exercise>
          </section>
    <section class="references" id="sect-00011">
    <para id="para-00042">Annie E. Casey Foundation. (2023). <emphasis effect="italics">Defining LGBTQ terms and concepts.</emphasis> https://www.aecf.org/blog/lgbtq-definitions/</para>
    <para id="para-00043">Barredo, J. O. (2020). Room assignments, gender identity, and gender expression: A case study on caring for transgender patients. <emphasis effect="italics">MedSurg Nursing, 29</emphasis>(4), 237–244.</para>
    <para id="para-00044">Boston University Chobanian &amp; Avedisian School of Medicine. (n.d.). <emphasis effect="italics">Practical guidelines for transgender hormone treatment</emphasis>. https://www.bumc.bu.edu/endo/clinics/transgender-medicine/guidelines/</para>
    <para id="para-00045">Brooker, A. S., &amp; Loshak, H. (2020). <emphasis effect="italics">Gender affirming therapy for gender dysphoria: A rapid qualitative review</emphasis>, Project Number RC1266-000. Canadian Agency for Drugs and Technologies in Health. https://www.cadth.ca/gender-affirming-therapy-gender-dysphoria-rapid-qualitative-review</para>
    <para id="para-00046">Centers for Disease Control and Prevention. (2023). <emphasis effect="italics">Transgender persons</emphasis>. https://www.cdc.gov/lgbthealth/transgender.htm</para>
    <para id="para-00047">Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F. L., Monstrey, S. J., Motmans, J., Nahata, L., Nieder, T. O., … Arcelus, J. (2022). Standards of care for the health of transgender and gender diverse people, version 8. <emphasis effect="italics">International Journal of Transgender Health, 23</emphasis>(Suppl 1), S1–S259. https://doi.org/10.1080/26895269.2022.2100644</para>
    <para id="para-00048">DailyMed. (Updated May 18, 2020). <emphasis effect="italics">Androderm—Testosterone patch.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e58a5328-fdd9-40cb-a19f-8ed798989b9c</para>
    <para id="para-00049">DailyMed. (Updated November 1, 2020). <emphasis effect="italics">Androgel—Testosterone gel.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8677ba5b-8374-46cb-854c-403972e9ddf3</para>
    <para id="para-00050">DailyMed. (Updated August 24, 2021).<emphasis effect="italics"> Aveed—Testosterone undecanoate injection</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045</para>
    <para id="para-00051">DailyMed. (Updated March 3, 2023). <emphasis effect="italics">Danazol capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55ad6325-16f6-4f0c-a1dc-734847052d0b</para>
    <para id="para-00052">DailyMed. (Updated November 1, 2021). <emphasis effect="italics">Estradiol tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333d92f-2585-4b99-aaea-87c01c95125e</para>
    <para id="para-00053">DailyMed. (Updated December 12, 2018). <emphasis effect="italics">Finasteride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81b424d3-8418-4497-9395-59eae6755230</para>
    <para id="para-00054">DailyMed. (Updated April 27, 2022). <emphasis effect="italics">Leuprolide acetate kit.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19afe51a-3b2d-4286-ad32-992a34bba648</para>
    <para id="para-00055">DailyMed. (Updated November 20, 2020). <emphasis effect="italics">Medroxyprogesterone acetate tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2627eb11-06bf-4a45-9172-094468e3ca07</para>
    <para id="para-00056">DailyMed. (Updated January 20, 2023). <emphasis effect="italics">Spironolactone tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c23b6b9b-aec3-48a8-a518-76e4097f6479</para>
    <para id="para-00057">DailyMed. (Updated August 24, 2018). <emphasis effect="italics">Testopel—Testosterone pellet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b9c0b1-5884-11e4-8ed6-0800200c9a66</para>
    <para id="para-00058">DailyMed. (Updated October 31, 2018). <emphasis effect="italics">Testosterone cypionate injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7b57b68-dca6-4df2-b3f2-7017d7b69f17</para>
    <para id="para-00059">DailyMed. (Updated November 12, 2021). <emphasis effect="italics">Testosterone enanthate injection, solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e89d6458-428c-4256-97a3-f1fa851293c1</para>
    <para id="para-00060">Deutsch, M. B. (2016). <emphasis effect="italics">Overview of feminizing hormone therapy.</emphasis> University of California San Francisco Transgender Care Navigation Program. https://transcare.ucsf.edu/guidelines/feminizing-hormone-therapy</para>
    <para id="para-00061">Dickerson, S. (2022). Nursing care for transgender and nonbinary patients: An educational model for forensic nurse examiners. <emphasis effect="italics">Doctor of Nursing Practice Projects,</emphasis> <emphasis effect="italics">42</emphasis>. https://scholarworks.seattleu.edu/dnp-projects/42</para>
    <para id="para-00062">Gonzales, G., &amp; Henning-Smith, C. (2017). Barriers to care among transgender and gender nonconforming adults. <emphasis effect="italics">Milbank Quarterly</emphasis>, <emphasis effect="italics">95</emphasis>(4), 726–748. https://doi.org/10.1111/1468-0009.12297</para>
    <para id="para-00063">Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., &amp; T’Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. <emphasis effect="italics">Journal of Clinical Endocrinology and Metabolism, 102</emphasis>(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658</para>
    <para id="para-00064">Hruz, P. W. (2020). Deficiencies in scientific evidence for medical management of gender dysphoria. <emphasis effect="italics">Linacre Quarterly, 87</emphasis>(1), 34–42. https://doi.org/10.1177/0024363919873762</para>
    <para id="para-00065">International Society for Sexual Medicine. (n.d.). <emphasis effect="italics">What is the difference between transsexual and transgender?</emphasis> https://www.issm.info/sexual-health-qa/what-is-the-difference-between-transsexual-and-transgender</para>
    <para id="para-00066">Kinney, M. K., &amp; Cosgrove, D. (2022). “Truly listen to us”: Recommendations for health professionals to bolster wellbeing of nonbinary individuals. <emphasis effect="italics">International Journal of Environmental Research and Public Health, 19</emphasis>, 1–22. https://doi.org/10.3390%2Fijerph19159032</para>
    <para id="para-00067">Kirkland, A., Talesh, S., &amp; Perone, A. K. (2021). Health insurance rights and access to health care for trans people: The social construction of medical necessity. <emphasis effect="italics">Law and Society Review</emphasis>, <emphasis effect="italics">55</emphasis>(4), 539–562. https://doi.org/10.1111/lasr.12575</para>
    <para id="para-00068">Klein, D. (2023). Caring for military-affiliated transgender and gender-diverse youths: A call for protections. <emphasis effect="italics">American Journal of Public Health, 113</emphasis>(3), 251–255<emphasis effect="italics">.</emphasis> https://ajph.aphapublications.org/doi/10.2105/AJPH.2022.307163</para>
    <para id="para-00069">Matsuda, J. (2022). Leave them kids alone: State constitutional protections for gender-affirming healthcare. <emphasis effect="italics">Washington &amp; Lee Law Review</emphasis>, <emphasis effect="italics">79</emphasis>(4), 1597–1654. https://scholarlycommons.law.wlu.edu/cgi/viewcontent.cgi?article=4796&amp;context=wlulr</para>
    <para id="para-00070">Mayo Clinic. (2021a, March 18). <emphasis effect="italics">Feminizing hormone therapy</emphasis>. https://www.mayoclinic.org/tests-procedures/feminizing-hormone-therapy/about/pac-20385096</para>
    <para id="para-00071">Mayo Clinic. (2021b, July 21). <emphasis effect="italics">Masculinizing hormone therapy</emphasis>. https://www.mayoclinic.org/tests-procedures/masculinizing-hormone-therapy/about/pac-20385099</para>
    <para id="para-00072">Milionis, C., Koukkou, E., &amp; Ilias, I. (2022). Conundrums in the medical treatment of transgender persons. <emphasis effect="italics">Endocrine, Metabolic &amp; Immune Disorders, 22,</emphasis> 795–797. https://doi.org/10.2174/1871530322666220223161227</para>
    <para id="para-00073">Mount Sinai. (n.d.-a). <emphasis effect="italics">Trans-masculine (female to male) surgeries</emphasis>. https://www.mountsinai.org/locations/center-transgender-medicine-surgery/care/surgery/female-to-male</para>
    <para id="para-00074">Mount Sinai. (n.d.-b). <emphasis effect="italics">Trans-feminine (male-to-female) surgeries</emphasis>. https://www.mountsinai.org/locations/center-transgender-medicine-surgery/care/surgery/male-to-female</para>
    <para id="para-00075">National Center for Transgender Equality. (2016, July 9). <emphasis effect="italics">Frequently asked questions about transgender people.</emphasis> https://transequality.org/issues/resources/frequently-asked-questions-about-transgender-people</para>
    <para id="para-00076">Rafferty, J., Committee on Psychosocial Aspects of Child and Family Health; Committee on Adolescence; Section on Lesbian, Gay, Bisexual, and Transgender Health and Wellness. (2018). Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. <emphasis effect="italics">Pediatrics, 142</emphasis>(4), e20182162. https://doi.org/10.1542/peds.2023-063756</para>
    <para id="para-00077">Ramsay, A., &amp; Safer, J. D. (2023). Update in adult transgender medicine. <emphasis effect="italics">Annual Review of Medicine, 74,</emphasis> 117–124. https://doi.org/10.1146/annurev-med-020222-121106</para>
    <para id="para-00078">Rodriguez-Wallberg, K., Obedin-Maliverd, J., Taylor, B., Van Mellog, N., Tilleman, K., &amp; Nahatai, L. (2022). Reproductive health in transgender and gender diverse individuals: A narrative review to guide clinical care and international guidelines. <emphasis effect="italics">International Journal of Transgender Health, 24</emphasis>(1), 7–25. https://doi.org/10.1080/26895269.2022.2035883</para>
    <para id="para-00079">Selby, A. (2022). <emphasis effect="italics">How to identify and treat gender dysphoria</emphasis>. Healthline. https://www.healthline.com/health/gender-dysphoria</para>
    <para id="para-00080">Sirufo, M. M., Magnanimi, L. M., Ginaldi, L., &amp; De Martinis, M. (2022). Breaking down barriers to facilitate access to healthcare among transgender people. <emphasis effect="italics">The Journal of Adolescent Health, 71</emphasis>(6), 768–769. https://doi.org/10.1016/j.jadohealth.2022.07.010</para>
    <para id="para-00081">T’Sjoen, G., Arcelus, J., Gooren, L., Klink, D. T., &amp; Tangpricha, V. (2019). Endocrinology of transgender medicine. <emphasis effect="italics">Endocrinology Review, 40</emphasis>(1), 97–117. https://doi.org/10.1210/er.2018-00011</para>
    <para id="para-00082">Unger, C. A. (2016). Hormone therapy for transgender patients. <emphasis effect="italics">Translational Andrology and Urology, 5</emphasis>(6), 877–884. https://doi.org/10.21037/tau.2016.09.04</para>
    <para id="para-00083">Webb, A., McManus, D., Rouse, G. E., Vonderheyde, R., &amp; Topal, J. E. (2020). Implications for medication dosing for transgender patients: A review of the literature and recommendations for pharmacists. <emphasis effect="italics">American Journal of Health-System Pharmacists, 77</emphasis>(6), 427–433. https://doi.org/10.1093/ajhp/zxz355</para>
    <para id="para-00084">Zaliznyak, M., Bresee, C., &amp; Garcia, M. M. (2020). Age at first experience of gender dysphoria among transgender adults seeking gender-affirming surgery. <emphasis effect="italics">JAMA Network Open, 3</emphasis>(3), e201236. https://doi.org/10.1001/jamanetworkopen.2020.1236</para>
    </section>
    </content>
</document>